The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Gout & Excess Risk of Severe SARS-CoV-2 Infection

Gout & Excess Risk of Severe SARS-CoV-2 Infection

January 3, 2023 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Background & Objectives

Patients with gout often have multiple comorbidities, making them susceptible to SARS-CoV-2 infection and poor outcomes. Xie et al. set out to examine the association between gout and the risk of SARS-CoV-2 infection and severe outcomes, especially in patients vaccinated against COVID-19. By identifying individuals who are susceptible to breakthrough COVID-19 and severe outcomes despite vaccination, doctors may identify populations who would benefit from other risk-mitigating strategies (e.g., pre-exposure prophylaxis).

You Might Also Like
  • Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination
  • More Evidence Links Pediatric Inflammatory Multisystem Syndrome to SARS-CoV-2
  • Outcomes in Patients with Rheumatic Diseases & COVID-19

Methods

Xie et al. conducted two cohort studies using The Health Improvement Network (THIN) in the U.K. The database consists of ~17 million individuals from 790 general practices whose healthcare information is systematically recorded by general practitioners and sent anonymously to THIN. Individuals with gout and those without gout from the general population were followed up from Dec. 8, 2020 to Oct. 31, 2021. Xie et al. estimated the rate difference and hazard ratio (HR) of SARS-CoV-2 infection and severe outcomes (i.e., hospitalization and death within 30 days after SARS-CoV-2 infection) for individuals with gout vs. those without gout using a Cox proportional hazards model according to SARS-CoV-2 vaccination status. The researchers adjusted for potential confounders by using overlap weighting of exposure scores.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Results

Among the vaccinated cohort, 1,955 cases of breakthrough COVID-19 infection occurred in individuals with gout (4.68 cases per 1,000 person-months), and 52,468 cases occurred in 1,336,377 individuals without gout (3.76 cases per 1,000 person-months). The adjusted rate difference of breakthrough infection was 0.91 cases per 1,000 person-months (95% confidence interval [CI] 0.62–1.20 cases per 1,000 person-months), and the adjusted HR was 1.24 (95% CI 1.19–1.30). Based on these data, gout was also associated with an increased risk of hospitalization and death. Women with gout also exhibited an increased risk of hospitalization and death. Similar associations with gout were observed in the unvaccinated cohort.

Conclusions

In this large, population-based study, Xie et al. found that the risks of SARS-CoV-2 infection, 30-day hospitalization and 30-day death were higher among individuals with gout than individuals without gout in the general population, irrespective of COVID-19 vaccination status. In addition, women with gout may be more susceptible to severe outcomes of COVID-19 (i.e., hospitalization and death) than men with gout. These findings suggest that additional measures should be considered to mitigate the risk of SARS-CoV-2 infection and potential severe outcomes for individuals with gout, especially women and even after vaccination.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For full study details, including source material, refer to the full article. 

Pages: 1 2 | Single Page

Filed Under: Conditions, Crystal Arthritis Tagged With: Arthritis & Rheumatology, comorbidities, COVID-19, Gout, risk

You Might Also Like:
  • Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination
  • More Evidence Links Pediatric Inflammatory Multisystem Syndrome to SARS-CoV-2
  • Outcomes in Patients with Rheumatic Diseases & COVID-19
  • Some Rheumatic Diseases Tied to Higher Risk of Severe COVID-19

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)